Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel

Urology

Volumn 52, Issue 1, 1998, Pages 56-60

  Dimopoulos, Meletios A ^a,b   Deliveliotis, Charalambos ^a   Moulopoulos, Lia A ^a   Papadimitriou, Christos ^a   Mitropoulos, Dionysios ^a   Anagnostopoulos, Athanasios ^a   Athanassiades, Peter ^a   Dimopoulos, Constantinos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; METASTASIS; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TREATMENT OUTCOME; UROGENITAL TRACT CANCER;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PACLITAXEL; TAXOIDS;

EID: 0032127550     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00150-2     Document Type: Article

References (11)

1. 1. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64: 2448-2458, 1989.
2. 2. Sternberg CN: The treatment of advanced bladder cancer. Ann Oncol 6: 113-126, 1995.
3. 3. Einhorn LH, Roth BJ, Ansari R, et al: Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12: 2271-2276, 1994.
4. 4. Roth BJ, Dreicer R, Einhorn LH, et al: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264-2270, 1994.
5. 5. Leibovitch I, Ben-Chaim J, Ramon J, et al: The significance of ureteral obstruction in invasive transitional cell carcinoma of the urinary bladder. J Surg Oncol 52: 31-35, 1993.
6. 6. Mc Caffrey J, Hilton S, Mazumdar M, et al: Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 15: 1853-1857, 1997.
7. 7. De Wit R, Stoter G, and Blanc C: Phase II study of first-line doxetaxel (Taxotere) in patients with metastatic urothelial cancer. Ann Oncol 5 (Suppl 8): 67, 1994.
8. 8. Gaillard C, Monsarrat B, and Unilhorgne M: Docetaxel metabolism in the rat in vivo and in vitro. Proc Am Assoc Cancer Res 35: 428, 1994.
9. 9. MacGregor PS, Montie JE, and Straffon RA: Cutaneous ureterostomy as palliative diversion in adults with malignancy. Urology 30: 31-34, 1987.
10. 10. Von Sonnenberg E, D'Agostino HB, O'Laoide R, et al: Malignant ureteral obstruction: treatment with metal stents -technique, results, and observations with percutaneous intraluminal ureteral stents. Radiology 191: 765-768, 1994.
11. 11. Dreicer R, Gustin DM, See WA, et al: Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 156: 1606-1608, 1996.